

09/308,027

PAIDC

QUERY CONTROL FORM		RTIS USE ONLY	
Application No. <u>09308027</u>	Prepared by <u>M. RUSTIA</u>	Tracking Number <u>05976017</u>	
Examiner-GAU <u>CHAN-1644</u>	Date <u>7-26-04</u>	Week Date <u>07-05-04</u>	
	No. of queries <u>2</u>	<u>IPW</u>	

JACKET

a. Serial No.	f. Foreign Priority	k. Print Claim(s)	p. PTO-1449
b. Applicant(s)	g. Disclaimer	l. Print Fig.	q. PTOL-85b
c. Continuing Data	h. Microfiche Appendix	m. Searched Column	r. Abstract
<input checked="" type="checkbox"/> d. PCT	i. Title	n. PTO-270/328	s. Sheets/Figs
e. Domestic Priority	j. Claims Allowed	o. PTO-892	t. Other

SPECIFICATION

- a. Page Missing
- b. Text Continuity
- c. Holes through Data
- d. Other Missing Text
- e. Illegible Text
- f. Duplicate Text
- g. Brief Description
- h. Sequence Listing
- i. Appendix
- j. Amendments
- k. Other

MESSAGE

PCT Legal Affairs Office, 308-6515① PCT 903 form found in the file is illegible.② DO/EO form is not found inside the file.Please advise.

CLAIMS

- a. Claim(s) Missing
- b. Improper Dependency
- c. Duplicate Numbers
- d. Incorrect Numbering
- e. Index Disagrees
- f. Punctuation
- g. Amendments
- h. Bracketing
- i. Missing Text
- j. Duplicate Text
- k. Other

RESPONSE

See M903 of 10-28-05 or 9-20-99 and attached page.Thank you,
initials MRinitials DGO

Peptide immunotherapeutic agent

Patent number: AU4964997

Publication date: 1998-06-03

Inventor: SONE TOSHIO; KUME AKINORI; DAIRIKI KAZUO;
KINO KOHSUKE

Applicant: MEIJI MILK PROD CO LTD

Classification:

- international: **C07K14/415; G01N33/569; A61K38/00; C07K14/415;
G01N33/569; A61K38/00; (IPC1-7): A61K39/35;
A61K38/00; A61K39/36; G01N33/53**

- european: C07K14/415; G01N33/569H4

Application number: AU19970049649D 19971112

Priority number(s): JP19960302053 19961113; WO1997JP04129 19971112

Also published as:



EP0958834 (A1)

WO9820902 (A1)

WO9820902 (A1)

AU736977 (B2)

Report a data error here

Abstract not available for AU4964997

Abstract of corresponding document: **EP0958834**

A peptide-based immunotherapeutic agent effective for every allergy patient is provided. A reagent for typing HLA class II molecules of the patient to be used in selecting a peptide-based immunotherapeutic agent effective for every allergy patient is also provided. The peptide-based immunotherapeutic agent enables the optimal peptide-based immunotherapy for each patient, so that a marked improvement in peptide-immunotherapy can be expected. The peptide-based immunotherapeutic agent is also effective for patients who cannot be treated by peptide-based immunotherapy using major antigen peptide recognized in a particular patient population. Furthermore, the peptide-based immunotherapeutic agent enables simple and easy typing of HLA class II molecules of allergy patients.

Data supplied from the **esp@cenet** database - Worldwide